Nature Reviews. Clinical Oncology

Our medical research library holds 8 studies published in Nature Reviews. Clinical Oncology (2010–2023). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 3 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it. For 1 study PubMed has no abstract for, we give the abstract printed in the article or, where there is none, a summary we wrote from it, each labeled as such.

About the journal

• Publisher: Nature Pub. Group
• Published: 2009 to the present, England
• Language: English
• ISSN: 1759-4774 (print), 1759-4782 (electronic)
• Continues: Nature Clinical Practice. Oncology
• Its record in the NLM Catalog

2020s

• The global burden of lung cancer: current status and future trends. A. Leiter, R.R. Veluswamy, J.P. Wisnivesky. 2023;20(9):624-639. Review PubMed · Publisher

  Abstract

  Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer incidence and mortality rates differ substantially across the world, reflecting varying patterns of tobacco smoking, exposure to environmental risk factors and genetics. Tobacco smoking is the leading risk factor for lung cancer. Lung cancer incidence largely reflects trends in smoking patterns, which generally vary by sex and economic development. For this reason, tobacco control campaigns are a central part of global strategies designed to reduce lung cancer mortality. Environmental and occupational lung cancer risk factors, such as unprocessed biomass fuels, asbestos, arsenic and radon, can also contribute to lung cancer incidence in certain parts of the world. Over the past decade, large-cohort clinical studies have established that low-dose CT screening reduces lung cancer mortality, largely owing to increased diagnosis and treatment at earlier disease stages. These data have led to recommendations that individuals with a high risk of lung cancer undergo screening in several economically developed countries and increased implementation of screening worldwide. In this Review, we provide an overview of the global epidemiology of lung cancer. Lung cancer risk factors and global risk reduction efforts are also discussed. Finally, we summarize lung cancer screening policies and their implementation worldwide.

  © 2023. Springer Nature Limited.

• Immunotherapy approaches for malignant pleural mesothelioma. D.A. Fennell, S. Dulloo, J. Harber. 2022;19(9):573-584. Review PubMed · Publisher

  Abstract

  Over the past decade, immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. In mesothelioma, a rare cancer with a dismal prognosis generally caused by exposure to asbestos, treatment with single or dual ICIs results in robust improvements in overall survival over previous standard-of-care therapies, both in the first-line and relapsed disease settings. Predictive biological features that underpin response to ICIs remain poorly understood; however, insights into the immune microenvironment and genomic landscape of mesothelioma as well as into their association with response or acquired resistance to ICIs are emerging. Several studies of rational combinations involving ICIs with either another ICI or a different agent are ongoing, with emerging evidence of synergistic antitumour activity. Non-ICI-based immunotherapies, such as peptide-based vaccines and mesothelin-targeted chimeric antigen receptor T cells, have demonstrated promising efficacy. Moreover, results from pivotal trials of dendritic cell vaccines and viral cytokine delivery, among others, are eagerly awaited. In this Review, we comprehensively summarize the key steps in the development of immunotherapies for mesothelioma, focusing on strategies that have led to randomized clinical evaluation and emerging predictors of response. We then forecast the future treatment opportunities that could arise from ongoing research.

  © 2022. Springer Nature Limited.

• Benefit with first-line ICIs in mesothelioma. D. Romero. 2021;18(4):194. Comment PubMed · Publisher

• CAR T cells show promise in mesothelioma. D. Killock. 2021;18(9):541. Comment PubMed · Publisher

2010s

• A better AI-based tool for mesothelioma. D. Romero. 2019;16(12):722. Comment PubMed · Publisher

• Immunotherapy trials in mesothelioma - promising results, but don't stop here. A.K. Nowak, P.M. Forde. 2019;16(12):726-728. Comment PubMed · Publisher

  Abstract

  In the past few years, several studies have addressed the possibility of using immunotherapies to treat patients with mesothelioma. Herein, we discuss two recent trials, one testing the immune-checkpoint inhibitor nivolumab and the other testing a mesothelin-directed therapeutic vaccine, and reflect on the advances and challenges remaining in this research area.

  PubMed has no abstract for this study. This is the authors' abstract, copied from the article.

• Mesothelioma risk genes revealed. P. Sidaway. 2018;15(11):655. Comment PubMed · Publisher

• Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. W.P. Ceelen, M.F. Flessner. 2010;7(2):108-15. Review PubMed · Publisher

  Abstract

  In patients with tumors confined to the peritoneal cavity, there is established pharmacokinetic and tumor biology-related evidence that intraperitoneal drug administration is advantageous. Three large randomized trials in patients with stage III ovarian cancer who underwent optimal cytoreduction have demonstrated a significant survival benefit when intraperitoneal chemotherapy was added to systemic therapy. Although intraperitoneal therapy is associated with locoregional toxic effects, recent trials suggest that with some modification of the local delivery methods this approach is safe in 80% of patients in an ambulatory setting. Surgical cytoreduction immediately followed by intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC) ensures intraperitoneal delivery of the drug to all peritoneal surfaces and the advantages of combined hyperthermia to be exploited. An increasing number of centers are initiating this multimodality therapy in ovarian cancer and colorectal cancer. Clearly, intraperitoneal drug delivery is an important adjunct to surgery and systemic chemotherapy in selected patients. The optimal drug, dose and schedule for intraperitoneal delivery, the exact role of added HIPEC compared with cytoreduction alone, and the potential role of HIPEC in ovarian cancer and peritoneal mesothelioma are still undefined. Several randomized controlled trials addressing these uncertainties have been initiated.

Browse every journal in the library or the library by type of article, or return to medical research.